Curing Hepatitis B with Combination Therapy
Curing hepatitis B is at the forefront of ContraVir’s research and business strategy. Similar to other major viral infections like hepatitis C and HIV, experts now believe that combining different drugs that can work together against HBV into a single regimen will be the most likely way to achieve a cure. A cure for hepatitis B may be through full eradication of the virus from the body (similar to hepatitis C) or what is known as a “functional cure” whereby viral levels are minimal and any negative effects are eliminated with continuous therapy (similar to HIV).
The mechanisms of action of ContraVir’s two HBV drugs TXL™ and CRV431 are distinct and complementary to each other, inhibiting viral replication at multiple different points in the HBV life cycle. Both drugs are next-generation derivatives of proven antiviral compounds and have demonstrated potentially best-in-class potency in vitro. Higher potency helps minimize the dose required for antiviral activity, as well as potentially reduce any side effects. It also maximizes the opportunity to use TXL™ and CRV431 in combination with each other and additional molecules to create a uniquely powerful and potentially curative anti-HBV regimen. ContraVir is focused on advancing its HBV portfolio and working towards a functional cure for hepatitis B.